Free Trial

Agios Pharmaceuticals (AGIO) SEC Filings & 10K Form

Agios Pharmaceuticals logo
$35.22 +1.47 (+4.34%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$35.22 +0.00 (+0.01%)
As of 02/21/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Agios Pharmaceuticals SEC Filings

DateFilerForm TypeView
02/14/2025
1:35 PM
Agios Pharmaceuticals (Subject)
BB BIOTECH AG (Filed by)
Form SCHEDULE 13G/A
02/13/2025
8:26 AM
Agios Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
5:32 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2025
5:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2025
11:02 AM
Agios Pharmaceuticals (Subject)
Farallon Capital Partners, L.P. (Filed by)
Form SCHEDULE 13G/A
01/13/2025
6:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
4:05 PM
Agios Pharmaceuticals (Issuer)
Milanova Tsveta (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
5:36 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
3:14 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
3:17 PM
Agios Pharmaceuticals (Subject)
Ballal Rahul D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/08/2024
1:40 PM
Agios Pharmaceuticals (Subject)
Farallon Capital Partners, L.P. (Filed by)
Form SC 13G/A
10/31/2024
8:20 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/31/2024
5:56 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2024
3:15 PM
Agios Pharmaceuticals (Issuer)
Jones Cecilia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:12 PM
Agios Pharmaceuticals (Issuer)
Smith Cynthia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:15 PM
Agios Pharmaceuticals (Issuer)
Ballal Rahul D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2024
4:15 PM
Agios Pharmaceuticals (Issuer)
Goff Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/01/2024
8:49 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2024
6:03 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2024
3:30 PM
Agios Pharmaceuticals (Issuer)
Gheuens Sarah (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:06 PM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
4:29 PM
Agios Pharmaceuticals (Issuer)
Schenkein David P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:31 PM
Agios Pharmaceuticals (Issuer)
FOUSE JACQUALYN A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:32 PM
Agios Pharmaceuticals (Issuer)
Foster-Cheek Kaye I (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:13 PM
Agios Pharmaceuticals (Issuer)
CAPELLO JEFFREY D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:15 PM
Agios Pharmaceuticals (Issuer)
Owen Catherine E. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:18 PM
Agios Pharmaceuticals (Issuer)
Scadden David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:19 PM
Agios Pharmaceuticals (Issuer)
Ho Maykin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:20 PM
Agios Pharmaceuticals (Issuer)
Smith Cynthia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:22 PM
Agios Pharmaceuticals (Issuer)
Ballal Rahul D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
6:50 PM
Agios Pharmaceuticals (Subject)
Goff Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2024
3:14 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2024
6:09 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
8:20 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2024
6:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2024
3:03 PM
Agios Pharmaceuticals (Issuer)
FOUSE JACQUALYN A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
5:47 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
5:49 PM
Agios Pharmaceuticals (Issuer)
Foster-Cheek Kaye I (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
3:26 PM
Agios Pharmaceuticals (Subject)
Foster-Cheek Kaye I (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2024
5:05 PM
Agios Pharmaceuticals (Subject)
Foster-Cheek Kaye I (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2024
6:06 PM
Agios Pharmaceuticals (Subject)
Foster-Cheek Kaye I (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Collect $7k per month from Tesla’s SECRET dividend (Ad)

There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?

Click here to uncover Tesla's hidden income secret.
02/26/2024
8:21 PM
Agios Pharmaceuticals (Subject)
Schenkein David P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/22/2024
4:43 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:AGIO) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners